BSI Partnering with Pharnext on $14.2M Initiative to Develop Biomarkers and Therapeutics for AD
November 19, 2010
BSI Partnering with Pharnext on $14.2M Initiative to Develop Biomarkers and Therapeutics for AD
Funded by the French innovation agency OSEO, the collaboration calls for the companies to develop a prototype blood-based protein biomarker test for Alzheimer's disease as well as a therapeutic for the disease and a companion diagnostic.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test
September 17, 2010 / ProteoMonitor - Initial Analysis of ADNI Plasma Proteome Data Suggests Possible Protein Signatures for Alzheimer's
December 10, 2010 / ProteoMonitor - BSI Merges with MBC to Secure Access to Nanoarray Technology and New Academic and Pharma Markets
September 17, 2010 / ProteoMonitor - BSI Closes €2.1M Funding Round for Development of Protein Biomarker Lung Cancer Test
July 23, 2010 / ProteoMonitor